Apr 13, 2022 / 12:45PM GMT
Gil Joseph Blum - Needham & Company, LLC, Research Division - Senior Analyst
Good morning, and welcome to day 3 of the Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Michael Parini, CEO of Freeline Therapeutics. As a reminder, any of you are who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window. And with that, Michael, you have the stage.
Michael J. Parini - Freeline Therapeutics Holdings plc - CEO, COO, President & Executive Director
Thanks, Gil. First of all, thank you to Needham and you for having us. We're excited to share a bit about the Freeline story. We do have a presentation to go through. We'll try to go through it quickly. And obviously, if there are questions that come up, we're happy to answer them. Some legal disclosures, but we can cover that.
So I think just at a high level, we're
Freeline Therapeutics Holdings PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers